Dr. Sisley will provide a deep dive into recent PTSD studies as well as an update on the lawsuit to force DEA to allow researchers to source cannabis through cultivators other than the monopoly held for decades by the University of Mississippi.  Dr. Sisley will then lay out a roadmap for how a molecule can make the journey to medicine. 

Dr. Woodcock reveals what Pharmacists are seeing and what the data says about dosing and treatments making an impact.

Learn how Silease has developed novel cannabinoid patches based on new topical delivery technology recognised by leading international companies in wound care and cosmetics. Silease delivery device can provide precise and continuous dosing over extended period of time with the possibility to adjust release of cannabinoids.

Join Ms. Gordy in a live Q and A entitled Insights on the Patient Experience.  She’ll share an overview of becoming a patient in New Jersey’s MMP and how the dispensary team helps patients navigate the program.  She welcomes any questions that you have regarding the patient experience!

Learn how Dr. Nethaji Gallage, CEO of the Denmark-based startup Octarine Bio is innovating by developing a biosynthetic platform for cannabinoid and psilocybin derivatives using microbial fermentation. Find out why Octarine’s mission to improve the health and well-being of people worldwide drives them to engineer microorganisms to produce a range of natural and novel cannabinoid and psilocybin derived molecules with improved pharmacokinetic and therapeutic properties. https://octarinebio.com/

This presentation will discuss PGx testing for cannabis and potential impacts on commonly prescribed pharmaceuticals, diving into the pharmacokinetics and pharmacogenomics involving the latest results in medical cannabis studies.

The therapeutic applications of medical cannabis and cannabinoid drugs is controversial, however the number of medical conditions in which cannabinoids and cannabis have shown promise as therapeutic treatments is expanding. The occurrence of side effects from cannabinoids is still a concern, especially with the wide variability in drug levels and response that has been observed. This is compounded by possible interactions with prescription drugs. Application of pharmacogenomics (PGx) and knowledge of drug-drug interactions could help patients and doctors navigate the complexities of combining prescription drugs and cannabis compounds. Genetic variants in several drug metabolizing enzymes may impact response to cannabinoids, including CYP3A4, CYP2C9, and CYP2C19. Furthermore, drug interactions caused by cannabinoids may also be mediated by drug metabolizing enzymes (e.g. CYP2C9, CYP2D6, CYP2B6, CYP1A1) and possibly drug transporters such as ABCB1. Understanding how commonly prescribed drugs and cannabinoids interact could help reduce risks associated with polydrug regimens, and possibly predict adverse reactions to cannabis and susceptibility to Cannabis Use Disorder.